<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > Clínica Universidad de Navarra > Oncología médica > DA - CUN - Oncología médica - Artículos de revista >

Combining chemotherapy and targeted therapies in metastatic colorectal cancer
Authors: Rodriguez, J. (Javier)
Zarate, R. (Ruth)
Bandres, E. (Eva)
Viudez, A. (A.)
Chopitea, A. (Ana)
Garcia-Foncillas, J. (Jesús)
Gil-Bazo, I. (Ignacio)
Keywords: Targeted therapy
Colorectal cancer
Issue Date: 2007
Publisher: Baishideng Publishing Group
Publisher version:
ISSN: 1007-9327
Citation: Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, Garcia-Foncillas J, et al. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007 Nov 28;13(44):5867-5876.
Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, cetuximab and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer.
Permanent link:
Appears in Collections:DA - CUN - Oncología médica - Artículos de revista

Files in This Item:
File:  World J Gastroenterol 2007. 5867.pdf
Size:  340,9 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.